Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

pharmafile | May 8, 2019 | News story | Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma 

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.

Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.

Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.

Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”

“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”  

The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.

Louis Goss

Related Content

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content